Medicare Enrolled
Dr. Christopher Lobo, MD
Medical Oncology · Port Charlotte, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lobo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lobo? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lobo
Dr. Christopher Lobo is a medical oncology in Port Charlotte, FL, with 19 years in practice. Based on federal Medicare data, Dr. Lobo performed 507,683 Medicare services across 9,652 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lobo received a total of $6,078 from 61 pharmaceutical and/or device companies across 349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lobo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 1% volume in FL$ $6,078 industry payments
Medicare Practice Summary
Medicare Utilization ↗507,683
Medicare services
Top 1% in FL for medical oncology
9,652
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~26,720 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 79,100 | $0 | $5 |
| Iron infusion (Feraheme) | 47,940 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 37,600 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 37,570 | $1 | $5 |
| Filgrastim injection (Nivestym) for white blood cells | 37,320 | $0 | $1 |
| Filgrastim injection (Zarxio) for white blood cells | 34,860 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 34,100 | $0 | $12 |
| Nivolumab injection (Opdivo) | 32,720 | $24 | $72 |
| Daratumumab injection (Darzalex) | 24,120 | $38 | $110 |
| Denosumab injection (Prolia/Xgeva) | 20,520 | $18 | $51 |
| Paclitaxel chemotherapy injection | 20,044 | $0 | $2 |
| Injection, durvalumab, 10 mg | 10,976 | $62 | $191 |
| Immune globulin infusion (Gammagard) | 9,792 | $36 | $108 |
| Dexamethasone injection (steroid) | 8,984 | $0 | $3 |
| Injection, mepolizumab, 1 mg | 8,100 | $23 | $72 |
| Epoetin alfa injection (Procrit) for anemia | 7,139 | $6 | $23 |
| Injection, docetaxel, 1 mg | 5,488 | $1 | $7 |
| Complete blood count (CBC) with differential | 5,002 | $8 | $29 |
| Blood draw (venipuncture) | 4,713 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 4,570 | $1 | $28 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,828 | $26 | $116 |
| Injection, bortezomib, 0.1 mg | 3,255 | $4 | $113 |
| Abatacept infusion (Orencia) | 2,975 | $34 | $140 |
| Office visit, established patient (30-39 min) | 2,852 | $95 | $339 |
| Anti-nausea injection (ondansetron/Zofran) | 2,516 | $0 | $9 |
| Injection of additional new drug or substance into vein | 2,508 | $12 | $61 |
| Omalizumab injection (Xolair) for asthma/allergy | 2,190 | $30 | $95 |
| Injection, leucovorin calcium, per 50 mg | 1,772 | $3 | $12 |
| Injection, fulvestrant, 25 mg | 1,500 | $8 | $132 |
| Drug injection, under skin or into muscle | 1,426 | $10 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 1,320 | $97 | $378 |
| Injection, fluorouracil, 500 mg | 1,130 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 834 | $47 | $189 |
| Injection, diphenhydramine hcl, up to 50 mg | 624 | $1 | $3 |
| Injection, carboplatin, 50 mg | 581 | $2 | $41 |
| Injection, cisplatin, powder or solution, 10 mg | 580 | $2 | $13 |
| Injection, potassium chloride, per 2 meq | 480 | $0 | $4 |
| Infusion into a vein for hydration, each additional hour | 472 | $10 | $42 |
| Administration of chemotherapy into vein, each additional hour | 434 | $21 | $79 |
| Infusion, normal saline solution , 1000 cc | 387 | $2 | $7 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 362 | $16 | $59 |
| Administration of additional new drug or substance into vein, 1 hour or less | 359 | $49 | $178 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 359 | $3 | $205 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 324 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 308 | $15 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 275 | $55 | $206 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 271 | $21 | $84 |
| Injection of drug or substance into vein | 268 | $28 | $156 |
| Ceftriaxone antibiotic injection | 228 | $0 | $3 |
| Injection, magnesium sulfate, per 500 mg | 228 | $1 | $2 |
| New patient office visit (45-59 min) | 192 | $123 | $453 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 183 | $25 | $89 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 180 | $3 | $11 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 176 | $126 | $637 |
| Infusion into a vein for hydration, 31-60 minutes | 163 | $24 | $156 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 147 | $135 | $562 |
| Administration of additional new drug or substance into vein using push technique | 145 | $42 | $170 |
| Prothrombin time test (blood clotting) | 132 | $4 | $15 |
| Red blood count, automated test | 117 | $4 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 112 | $15 | $56 |
| Automated urinalysis | 96 | $2 | $8 |
| Hospital follow-up visit, moderate complexity | 93 | $62 | $197 |
| Injection, zoledronic acid, 1 mg | 83 | $6 | $69 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 79 | $1 | $7 |
| Office visit, established patient (20-29 min) | 72 | $67 | $239 |
| New patient office visit, complex (60-74 min) | 68 | $164 | $585 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 62 | $4 | $15 |
| Drawing of blood for a medical problem | 61 | $65 | $277 |
| Injection, furosemide, up to 20 mg | 61 | $0 | $9 |
| Red blood count automated, with additional calculations | 59 | $5 | $20 |
| Initial hospital admission, high complexity | 46 | $137 | $556 |
| Office visit, established patient, complex (40-54 min) | 35 | $140 | $474 |
| Transitional care management services for problem of high complexity | 17 | $214 | $722 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.5% high complexity
84.6% medium
2.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,078
Total received (2018-2024)
Avg $868/year across 7 years
Bottom 48% in FL for medical oncology
61
Companies
349
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,025 (99.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$53 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$876
2023$854
2022$912
2021$708
2020$585
2019$830
2018$1,313
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$898
Janssen Biotech, Inc.
$642
Novartis Pharmaceuticals Corporation
$532
Merck Sharp & Dohme Corporation
$396
PFIZER INC.
$384
Celgene Corporation
$382
Daiichi Sankyo Inc.
$178
Lilly USA, LLC
$151
BeiGene USA, Inc.
$143
Astellas Pharma US Inc
$136
Regeneron Healthcare Solutions, Inc.
$128
Adamas Pharmaceuticals, Inc.
$125
Adaptive Biotechnologies Corporation
$118
ARRAY BIOPHARMA INC
$110
Merck Sharp & Dohme LLC
$105
Exelixis Inc.
$103
Genentech USA, Inc.
$101
Takeda Pharmaceuticals U.S.A., Inc.
$92
Incyte Corporation
$91
Seagen Inc.
$86
NanoString Technologies, Inc.
$72
PharmaEssentia USA Corporation
$70
Amgen Inc.
$66
AbbVie, Inc.
$62
Myovant Sciences Inc.
$61
ABBVIE INC.
$59
Eisai Inc.
$49
GENZYME CORPORATION
$46
Gilead Sciences, Inc.
$42
Mirati Therapeutics, Inc.
$38
AstraZeneca Pharmaceuticals LP
$38
Karyopharm Therapeutics Inc.
$34
AbbVie Inc.
$32
Secura Bio, Inc.
$32
GlaxoSmithKline, LLC.
$31
EMD Serono, Inc.
$30
TerSera Therapeutics LLC
$26
Telix Pharmaceuticals
$25
JAZZ PHARMACEUTICALS INC.
$24
Spectrum Pharmaceuticals Inc.
$24
TESARO, Inc.
$23
Pharmacyclics LLC, An AbbVie Company
$23
GE HealthCare
$22
Genmab U.S., Inc.
$22
Alnylam Pharmaceuticals Inc.
$20
Heron Therapeutics, Inc.
$18
Sun Pharmaceutical Industries Inc.
$17
Puma Biotechnology, Inc.
$17
Immunomedics, Inc.
$16
CTI BioPharma Corp.
$15
Sysmex Inostics Inc
$15
Horizon Pharma plc
$14
Jazz Pharmaceuticals Inc.
$14
SANOFI-AVENTIS U.S. LLC
$13
Bayer HealthCare Pharmaceuticals Inc.
$12
Taiho Oncology, Inc.
$12
Epizyme, Inc.,
$12
Aurobindo Pharma USA, Inc.
$12
SECURA BIO, INC.
$11
Rigel Pharmaceuticals, Inc.
$5
Veracyte, Inc.
$1
Top 3 companies account for 34.1% of total payments
Associated products mentioned in payments ›
ALIMTA · Alecensa · Avastin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · COPIKTRA · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ERLEADA · Enhertu · Epkinly · Erleada · FARYDAK · FRUZAQLA · Farydak · Folotyn · GIVLAARI · GOCOVRI · IBRANCE · ILLUCCIX · IMBRUVICA · IMFINZI · INJECTAFER · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nplate · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PLUVICTO · PROMACTA · PROSIGNA ASSAY · Padcev · Perjeta · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Rezlidhia · SANDOSTATIN · SARCLISA · SPRYCEL · SUTENT · TASIGNA · TAZVERIK · TECVAYLI · TEVIMBRA · TIVDAK · Trodelvy · VARUBI · VENCLEXTA · VOTRIENT · Venclexta · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · YONSA · ZEJULA · ZEPZELCA · ZOLADEX · Zevalin · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $1 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
5
Per 100K population
2.6
County median income
$66,154
Nearest hospital
Adventhealth Port Charlotte
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Lobo is a mixed practice specialist, with above-average Medicare volume (top 1% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Lobo experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Lobo performed 79,100 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lobo receive payments from pharmaceutical companies?
Yes. Dr. Lobo received a total of $6,078 from 61 companies across 349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lobo's costs compare to other medical oncologys in Port Charlotte?
Dr. Lobo's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lobo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Port Charlotte
Browse medical oncologys in Port Charlotte ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology